
Anti-Angiogenesis Strategies in Cancer Therapies
Description
Key Features
- Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
- Reviews FDA-approved anti-angiogenesis agents
- Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
- Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Readership
Table of Contents
- List of contributors
- Introduction
- Chapter 1: Angiogenesis and Anti-Angiogenesis Strategies in Cancer
- Abstract
- Process of Angiogenesis
- Angiogenesis in Cancer
- Strategies
- Current Examples of Cancer Treatment Agents that Block Angiogenesis
- Side Effects of Angiogenesis Inhibitors
- Angiogenesis and Angiogenesis Inhibitors: Potential Anti-cancer Therapeutic Efficacy
- Additional Anti-angiogenesis Strategies in Cancers
- Anti-angiogenesis Therapy in Hematologic Cancer: Multiple Myeloma
- Anti-coagulants and Angiogenesis
- Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs
- Standard Chemotherapy Versus Angiogenesis Inhibitors
- Anti-angiogenesis Agents and Thrombosis
- Diagnostic Imaging of Angiogenesis
- microRNA and Angiogenesis Modulation
- Chapter 2: Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques
- Abstract
- In Vivo Assays
- In Vitro Assays
- Three-Dimensional Matrix Array Ultrasound Molecular Imaging
- Coculture of Human Cancer Cells with Human Microvascular Endothelial Cells
- Discussion
- Conclusions
- Chapter 3: Anti-Angiogenesis in Multiple Myeloma
- Abstract
- Angiogenesis in Multiple Myeloma
- Thalidomide and its Analogs
- Bortezomib
- Tyrosine Kinase Inhibitors (TKIs)
- Zoledronic Acid
- Conclusions
- Acknowledgments
- Chapter 4: Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression
- Abstract
- Cancer-associated Thrombosis
- TF-VIIa-PAR2 Signaling Regulates Angiogenesis
- TF-VIIa-PAR2 Signaling Regulates Inflammation
- Role of TF-VIIa in Cellular Signaling
- Conclusions
- Chapter 5: microRNAs and Angiogenesis
- Abstract
- Introduction
- Specific miRNAs and Angiogenesis
- Chapter 6: Naturally Occurring Angiogenesis Inhibitors
- Abstract
- Introduction
- Nutraceutical-Derived Polyphenol Angiogenesis Inhibitors
- Marine Nonglycosaminoglycan Sulfated Glycans
- Natural Lipid Products
- Chapter 7: Integrin Antagonists and Angiogenesis
- Abstract
- Integrins
- Integrins and Signaling
- Cell Surface Membrane Integrins as Potential Drug Discovery Targets
- Diagnostics
- Integrin–Hormone Crosstalk: Integrin Receptor-Mediated Actions of Thyroid Hormone
- Conclusions
- Chapter 8: Tyrosine Kinase Inhibitors and Angiogenesis
- Abstract
- Introduction
- Examples of Specific TKIs
- Impact of Angiogenesis-Active TKIs on Clinical Outcomes
- Conclusions
- Chapter 9: Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis
- Abstract
- Introduction
- Thyroid Hormone is a Proangiogenic Agent and Tetrac is an Anti-angiogenic Agent
- Tetrac, NDAT, and Angiogenesis-relevant Gene Expression and microRNA Expression
- Tetrac, NDAT, and Actions of Vascular Growth Factors
- Tetrac and NDAT Actions on Endothelial Cells
- Anti-angiogenesis of NDAT in the Retina
- Anti-angiogenesis of NDAT in Human Tumor Xenografts
- Action of NDAT on Mechanisms of Vascular Sprouting
- Pharmacodynamics of NDAT
- Side Effect Profile of NDAT
- Conclusions
- Chapter 10: Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis
- Abstract
- Introduction
- Biomarkers of Angiogenesis
- Impact of Angiogenesis on Tumor Growth and Metastasis
- Current Anti-angiogenic Therapies
- Problems Encountered with Anti-angiogenic Therapy
- Distinctive Features of Tumor-Related Angiogenesis
- Novel Anti-angiogenesis Strategies
- Anti-angiogenesis and Nanotargeting
- Conclusions
- Chapter 11: Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics
- Abstract
- Introduction
- Angiogenesis
- Integrins
- Gene Therapy Delivery with Nanoparticles
- Conclusions
- Chapter 12: New Directions in Anti-Angiogenesis Research
- Abstract
- Introduction
- Projections
- Conclusions
- Acknowledgment
- Index
Product details
- No. of pages: 210
- Language: English
- Copyright: © Academic Press 2016
- Published: November 28, 2016
- Imprint: Academic Press
- eBook ISBN: 9780128026731
- Paperback ISBN: 9780128025765
About the Authors
Shaker Mousa
Dr. Mousa came to Albany College of Pharmacy and Health Sciences in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. Among Dr. Mousa's professional accomplishments are his contributions to many patents – he holds more than 250 U.S. and international patents – and to the discovery and development of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial perfusion and thrombus imaging agents. Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Journal of Pharmaceutical Sciences, Frontiers in Molecular Neuroscience, Clinical and Applied Thrombosis/Hemostasis, Applied Microbiology and Biotechnology, and PLoS Computational Biology.
Affiliations and Expertise
Paul Davis
Affiliations and Expertise
Ratings and Reviews
There are currently no reviews for "Anti-Angiogenesis Strategies in Cancer Therapies"